BD Reaches Settlement with the SEC
BD (Becton, Dickinson and Company) (NYSE: BDX), a renowned leader in medical technology, has announced a significant agreement to resolve an investigation by the U.S. Securities and Exchange Commission (SEC). This follows concerns regarding prior public disclosures related to the BD Alaris™ System.
Key Details of the Resolution
The SEC's findings, which BD does not admit or deny, concern events that took place over four years ago pertaining to the BD Alaris System. As part of the settlement, BD will pay $175 million to the SEC. Importantly, this amount was anticipated and reserved in the company’s fiscal year 2024 Form 10-K and accounted for in the fiscal year 2025 cash flow plan.
Following the resolution, BD confirmed that there will be no required financial restatements. The company emphasized that this settlement will not hinder its investments in innovation or its outlined capital allocation strategy. Furthermore, BD will maintain its fiscal guidance for 2025 without adjustments owing to this matter.
Commitment to Quality and Safety
BD's Alaris™ System plays a vital role in U.S. healthcare, demonstrating its effectiveness over many years in delivering essential IV therapies to patients. This includes its pivotal use during the COVID-19 pandemic. The updated BD Alaris™ System, which received FDA 510(k) clearance in July of this year, continues to evolve as BD enhances its fleet.
Improvements and Ethical Standards
In the aftermath of the SEC investigation, BD has taken proactive steps to revamp its operational and governance processes. The company is dedicated to upholding the highest ethical standards, ensuring that it produces safe, high-quality products while being a trustworthy partner to its customers and their patients.
About BD
BD is one of the largest global medical technology companies, committed to elevating global health through improved medical discovery, diagnostics, and care delivery. With a workforce exceeding 70,000 people, BD focuses on cultivating innovative technologies that enhance clinical outcomes and streamline healthcare processes.
By engaging with healthcare providers worldwide, BD seeks to tackle pressing health challenges and elevate healthcare standards. The company collaborates closely with customers to improve outcomes, reduce costs, and expand healthcare access.
Frequently Asked Questions
What was the SEC investigation about?
The SEC investigation focused on prior public disclosures regarding the BD Alaris™ System, dealing with events that transpired more than four years ago.
How much is BD paying to settle the SEC investigation?
BD has agreed to pay $175 million to the SEC as part of the settlement.
Will this settlement affect BD's financials?
No financial restatements will occur as a result of the settlement, and BD's investments in innovation remain unaffected.
What improvements has BD made post-investigation?
BD has enhanced its operational and governance processes to uphold integrity and ethical standards in its operations.
How long has the BD Alaris™ System been in use?
The BD Alaris™ System has been a crucial tool in patient care for several years, especially noted for its use during the COVID-19 pandemic.
